Extended Data Fig. 8: Immune characterization of PRDM1 cKO, c-MAF cKO and PRDM1/c-MAF cDKO before and after tumour challenge.

a, Analysis of steady-state immune system in wild-type, c-MAF cKO, PRDM1 cKO and PRDM1/c-MAF cDKO. Summary data for CD4, CD8, FOXP3, CD44, CD62L and CD69 expression in spleen from wild-type, c-MAF cKO, PRDM1 cKO and PRDM1/c-MAF cDKO mice. Data are mean ± s.e.m. from biologically independent animals. *P < 0.05, **P < 0.01, ****P < 0.0001, one-way ANOVA and Tukey’s multiple comparisons test. b, Co-inhibitory receptor expression in CD4⁺ TILs from PRDM1/c-MAF cDKO mice^. Top, representative flow cytometry data from three independent experiments for TILs from wild-type and PRDM1/c-MAF cDKO stained for PD-1, TIM-3, TIGIT, PDPN and PROCR expression. Bottom, summary data. Data are mean ± s.e.m. from biologically independent animals. *P < 0.05, two-sided t-test. c, Top, representative flow cytometry data from three independent experiments showing cytokine production from CD8⁺ TILs from wild-type and cDKO bearing B16F10 melanoma. Bottom, summary data. Data are mean ± s.e.m. from biologically independent animals. *P < 0.05, two-sided t-test. d, Co-inhibitory receptor expression on CD8⁺ TILs sorted from B16-OVA-bearing RAG1-knockout mice that were transferred with PRDM1/c-MAF cDKO (n = 4) or wild-type (n = 4) CD4⁺ and CD8⁺ T cells as indicated. Data are mean ± s.e.m. from biologically independent animals. *P < 0.05, one^-way ANOVA and Tukey’s multiple comparisons test. e, RAG1-knockout mice were transferred with either wild-type or cDKO CD4⁺ and CD8⁺ (2:1 CD4:CD8 ratio), followed by subcutaneous injection of MC38-OVA. Data are mean ± s.e.m. ****P < 0.0001, repeated measures ANOVA, Sidak’s multiple comparisons test. On day 14 after tumour implantation, mice were euthanized and TILs, spleen and draining lymph nodes were obtained. f, The frequency of antigen-specific CD8⁺ T cells in the draining lymph nodes of mice in e.